Grewal, Iqbal S.
Iqbal S Grewal researcher
VIAF ID: 41324499 (Personal)
Permalink: http://viaf.org/viaf/41324499
Preferred Forms
- 200 _ | ‡a Grewal ‡b Iqbal S.
- 100 1 _ ‡a Grewal, Iqbal S.
- 100 1 _ ‡a Grewal, Iqbal S.
- 100 1 _ ‡a Grewal, Iqbal S.
-
- 100 1 _ ‡a Grewal, Iqbal S.
-
- 100 1 _ ‡a Grewal, Iqbal S.
- 100 0 _ ‡a Iqbal S Grewal ‡c researcher
4xx's: Alternate Name Forms (1)
Works
Title | Sources |
---|---|
Activation and accumulation of B cells in TACI-deficient mice | |
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia | |
Antibody drug-conjugates targeting the tumor vasculature: Current and future developments | |
Antibody targeting of B-cell maturation antigen on malignant plasma cells | |
APRIL-deficient mice have normal immune system development | |
Autoimmune lpr/lpr mice deficient in CD40 ligand: spontaneous Ig class switching with dichotomy of autoantibody responses | |
BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2 | |
Blocking of CD27-CD70 pathway by anti-CD70 antibody ameliorates joint disease in murine collagen-induced arthritis. | |
CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. | |
CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | |
The CD40-CD154 system in anti-infective host defense | |
CD40 expression on antigen presenting cells and correlation with disease severity in atopic dermatitis | |
The CD40 ligand. At the center of the immune universe? | |
CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection | |
CD40 ligand-mediated interactions are involved in the generation of memory CD8(+) cytotoxic T lymphocytes (CTL) but are not required for the maintenance of CTL memory following virus infection | |
CD40L is important for induction of, but not response to, costimulatory activity. ICAM-1 as the second costimulatory molecule rapidly up-regulated by CD40L. | |
CD62L is required on effector cells for local interactions in the CNS to cause myelin damage in experimental allergic encephalomyelitis | |
Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. | |
Emerging CAR-T Cell Therapy for the Treatment of Triple Negative Breast Cancer | |
Emerging protein biotherapeutics | |
Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities | |
Expression of activated CDC42 induces T cell apoptosis in thymus and peripheral lymph organs via different pathways | |
Expression of transgene encoded TGF-beta in islets prevents autoimmune diabetes in NOD mice by a local mechanism. | |
Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency | |
Identification of a receptor for BLyS demonstrates a crucial role in humoral immunity | |
Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications | |
Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice | |
Impaired primary T cell responses in L-selectin-deficient mice | |
Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand | |
Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor | |
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. | |
New insights into insulin dependent diabetes mellitus from studies with transgenic mouse models | |
A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response | |
NTB-A, a new activating receptor in T cells that regulates autoimmune disease | |
Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker | |
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas | |
Preclinical characterization of SGN-70, a humanized antibody directed against CD70 | |
Preclinical pharmacokinetics, pharmacodynamics, and activity of a humanized anti-CD40 antibody (SGN-40) in rodents and non-human primates | |
Proapoptotic signaling activity of the anti-CD40 monoclonal antibody dacetuzumab circumvents multiple oncogenic transformation events and chemosensitizes NHL cells | |
Protective antibodies in murine Lyme disease arise independently of CD40 ligand | |
Recombinant humanized anti-CD40 monoclonal antibody triggers autologous antibody-dependent cell-mediated cytotoxicity against multiple myeloma cells | |
Reconstitution of invariant chain function in transgenic mice in vivo by individual p31 and p41 isoforms | |
Regulatory T Cell targeting in cancer: Emerging strategies in immunotherapy | |
Requirement for CD154 in the progression of atherosclerosis. | |
Response to 'Secreted IgM versus BLyS in germinal center formation' | |
The role of CD40 ligand in costimulation and T-cell activation | |
Role of L-selectin in the development of autoimmune diabetes in non-obese diabetic mice | |
A soluble BAFF antagonist, BR3-Fc, decreases peripheral blood B cells and lymphoid tissue marginal zone and follicular B cells in cynomolgus monkeys | |
TACI-ligand interactions are required for T cell activation and collagen-induced arthritis in mice | |
Targeting CD70 for human therapeutic use. | |
Targeting inflammatory cells to improve anti-VEGF therapies in oncology | |
Targeting of BAFF and APRIL for autoimmunity and oncology | |
Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges | |
Therapeutic targets of the TNF superfamily | |
TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L suppresses experimental autoimmune encephalomyelitis in mice | |
Transgenic monocyte chemoattractant protein-1 (MCP-1) in pancreatic islets produces monocyte-rich insulitis without diabetes: abrogation by a second transgene expressing systemic MCP-1 | |
Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues |